Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CU-10101
- Development stage
- Phase 1
- Lead developer
- Cutia Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
CU-10101 is a non-hormonal, small molecule drug developed for the topical treatment of mild to moderate atopic dermatitis. Unlike corticosteroids and calcineurin inhibitors, which are commonly used in this indication but can have significant side effects with long-term use, CU-10101 is designed to be applied directly to affected skin areas, potentially reducing systemic exposure and associated risks. The drug is currently being evaluated in Phase 1 clinical trials for safety, tolerability, pharmacokinetics, and preliminary efficacy in both healthy volunteers and patients with atopic dermatitis. Its precise mechanism of action has not been disclosed as of now[2][3][4][7][8].
Beyond the preview
Go deeper on CU-10101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CU-10101.